CID S.p.A.
8
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
13%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
The FLUYDO NC Post Market Clinical Follow-up Study
Role: collaborator
The Inperia Advance Post-Market Retrospective Study
Role: lead
The Isthmus Logic Post Market Clinical Follow-up Study
Role: lead
The Cre8™ BTK Post Market Clinical Follow-up Study
Role: lead
The EasyFlype/EasyHiFlype Post Market Clinical Follow-up Study.
Role: lead
RADIX 2 RENAL STENT Post-Market Retrospective Study
Role: lead
Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions
Role: lead
Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions
Role: lead
All 8 trials loaded